# Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

> **NCT06930352** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Uma Borate** · enrollment: 70 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **DRUG:** Cytarabine
- **PROCEDURE:** Echocardiography Test
- **DRUG:** Hydroxyurea
- **PROCEDURE:** Leukapheresis
- **PROCEDURE:** Multigated Acquisition Scan
- **OTHER:** Questionnaire Administration
- **DRUG:** Ziftomenib

## Key facts

- **NCT ID:** NCT06930352
- **Lead sponsor:** Uma Borate
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-10
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06930352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06930352, "Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06930352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*